In Section C, contributors will receive ABBV-744 and oral navitoclax. In Section D, members will receive ABBV-744 and ruxolitinib. Participants will get treatment until finally disorder progression or the members are not able to tolerate the study drugs. Ubiquitin-relevant proteins that regulate the stability of critical super enhancer-mediated proteins have https://gregoryesdoa.madmouseblog.com/12416431/the-2-minute-rule-for-is-abbv-744-effective-for-hematologic-cancers